Paper Details

  1. Home
  2. Paper Details

Sustained correction of hippocampal neurogenic and cognitive deficits after a brief treatment by Nutlin-3 in a mouse model of fragile X syndrome.

Author: FuYao, JavadiSahar, LiYue, ShengJie, WangDaifeng, ZhaoLucy, ZhaoXinyu

Journal ArticleAn article published in an academic or professional journal that reports original research or scholarly analysis.
Research Support, Non-U.S. Gov'tResearch funding provided by government agencies outside the United States.
Research Support, N.I.H., ExtramuralResearch funding provided by the NIH to external research institutions and researchers.

Overview

Nutlin-3, a MDM2 inhibitor, shows promise as a potential treatment for Fragile X syndrome (FXS). Previous research showed that Nutlin-3 rescues hippocampal neurogenesis and cognitive deficits in young adult FMR1-deficient mice. This study investigates whether Nutlin-3 treatment can have long-lasting therapeutic effects in FXS.
Paper Details　
Original Abstract of the Article :
Fragile X syndrome (FXS), the most prevalent inherited intellectual disability and one of the most common monogenic forms of autism, is caused by a loss of fragile X messenger ribonucleoprotein 1 (FMR1). We have previously shown that FMR1 represses the levels and activities of ubiquitin ligase MDM2 ...See full text at original site
Dr.Camel IconDr.Camel's Paper Summary Blogラクダ博士について

ラクダ博士は、Health Journal が論文の内容を分かりやすく解説するために作成した架空のキャラクターです。
難解な医学論文を、専門知識のない方にも理解しやすいように、噛み砕いて説明することを目指しています。

* ラクダ博士による解説は、あくまで論文の要点をまとめたものであり、原論文の完全な代替となるものではありません。詳細な内容については、必ず原論文をご参照ください。
* ラクダ博士は架空のキャラクターであり、実際の医学研究者や医療従事者とは一切関係がありません。
* 解説の内容は Health Journal が独自に解釈・作成したものであり、原論文の著者または出版社の見解を反映するものではありません。


引用元：
https://www.ncbi.nlm.nih.gov/pmc/articles/PMC9103116/

データ提供：米国国立医学図書館（NLM）

A Light at the End of the Tunnel: Restoring Hope for Fragile X Syndrome

Fragile X syndrome (FXS), a genetic disorder that affects brain development, poses a significant challenge in the field of [neurological disorders]. This study focuses on the potential of Nutlin-3, a therapeutic agent, to mitigate the cognitive and neurological deficits associated with FXS. The research provides a glimmer of hope for individuals with FXS and their families.

A New Path: Nutlin-3 Offers a Promise of Hope

The study demonstrates that Nutlin-3, a MDM2 inhibitor, can effectively improve hippocampal neurogenesis and cognitive function in mice with FXS. This finding offers a promising avenue for developing therapeutic interventions for FXS.

Unveiling the Potential: A Glimpse into a Brighter Future

The research emphasizes the need for further investigation into the long-term effects of Nutlin-3. While the current study provides a positive initial step, further research is essential to determine the full potential of Nutlin-3 in treating FXS.

Dr.Camel's Conclusion

This study is a ray of hope in the desert of FXS. The research provides a roadmap for potential therapeutic interventions, offering a glimmer of light for those affected by this complex disorder.

Date :
  1. Date Completed 2022-05-17
  2. Date Revised 2023-03-15
Further Info :

Pubmed ID

35549943

DOI: Digital Object Identifier

PMC9103116

Related Literature

Article Analysis
・Effective treatment of fragile x syndrome
SNS
PICO Info
in preparation
Languages

English

Positive IndicatorAn AI analysis index that serves as a benchmark for how positive the results of the study are. Note that it is a benchmark and requires careful interpretation and consideration of different perspectives.

This site uses cookies. Visit our privacy policy page or click the link in any footer for more information and to change your preferences.